Compare NORRIS MEDI. with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NORRIS MEDICINES vs MERCURY LAB. - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NORRIS MEDICINES MERCURY LAB. NORRIS MEDICINES/
MERCURY LAB.
 
P/E (TTM) x -4.0 16.1 - View Chart
P/BV x - 2.1 - View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 NORRIS MEDICINES   MERCURY LAB.
EQUITY SHARE DATA
    NORRIS MEDICINES
Mar-21
MERCURY LAB.
Mar-21
NORRIS MEDICINES/
MERCURY LAB.
5-Yr Chart
Click to enlarge
High Rs7768 0.8%   
Low Rs2267 0.9%   
Sales per share (Unadj.) Rs12.3571.7 2.1%  
Earnings per share (Unadj.) Rs-5.044.5 -11.2%  
Cash flow per share (Unadj.) Rs-4.360.5 -7.1%  
Dividends per share (Unadj.) Rs03.50 0.0%  
Avg Dividend yield %00.7 0.0%  
Book value per share (Unadj.) Rs-7.4307.5 -2.4%  
Shares outstanding (eoy) m10.001.20 833.3%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x0.40.9 40.4%   
Avg P/E ratio x-0.911.6 -7.8%  
P/CF ratio (eoy) x-1.08.6 -12.2%  
Price / Book Value ratio x-0.61.7 -35.8%  
Dividend payout %07.9 0.0%   
Avg Mkt Cap Rs m45621 7.2%   
No. of employees `000NANA-   
Total wages/salary Rs m3196 32.2%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m123686 17.9%  
Other income Rs m19 6.0%   
Total revenues Rs m123695 17.7%   
Gross profit Rs m-1796 -18.2%  
Depreciation Rs m719 34.7%   
Interest Rs m166 254.9%   
Profit before tax Rs m-4079 -50.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1026 37.7%   
Profit after tax Rs m-5053 -93.0%  
Gross profit margin %-14.214.0 -101.8%  
Effective tax rate %-24.332.5 -74.6%   
Net profit margin %-40.57.8 -520.6%  
BALANCE SHEET DATA
Current assets Rs m82378 21.8%   
Current liabilities Rs m117188 62.1%   
Net working cap to sales %-28.227.6 -102.2%  
Current ratio x0.72.0 35.1%  
Inventory Days Days366 550.0%  
Debtors Days Days53,283,600119,912,839 44.4%  
Net fixed assets Rs m89276 32.2%   
Share capital Rs m9912 827.2%   
"Free" reserves Rs m-174357 -48.6%   
Net worth Rs m-74369 -20.1%   
Long term debt Rs m15562 248.8%   
Total assets Rs m171654 26.2%  
Interest coverage x-1.413.3 -10.8%   
Debt to equity ratio x-2.10.2 -1,235.3%  
Sales to assets ratio x0.71.0 68.3%   
Return on assets %-19.59.1 -212.8%  
Return on equity %66.814.5 461.6%  
Return on capital %-29.119.8 -147.0%  
Exports to sales %1.81.0 181.2%   
Imports to sales %00.4 0.0%   
Exports (fob) Rs m27 32.3%   
Imports (cif) Rs mNA3 0.0%   
Fx inflow Rs m27 32.3%   
Fx outflow Rs m03 0.0%   
Net fx Rs m24 57.0%   
CASH FLOW
From Operations Rs m1182 13.6%  
From Investments Rs m-1-46 1.3%  
From Financial Activity Rs m-11-12 88.6%  
Net Cashflow Rs m024 -1.8%  

Share Holding

Indian Promoters % 34.0 73.7 46.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.1 0.0 -  
FIIs % 0.0 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 66.0 26.3 250.4%  
Shareholders   25,141 1,112 2,260.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NORRIS MEDICINES With:   SUN PHARMA    LUPIN    CIPLA    AUROBINDO PHARMA    DR. REDDYS LAB    



Today's Market

4 Reasons Why Sensex Plunged 634 Points Today(Closing)

Indian share markets witnessed negative trading activity throughout the day today and ended on a weak note.

Related Views on News

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

More Views on News

Most Popular

India's Best Semiconductor Stocks(Views On News)

Jan 7, 2022

Modern wars are fought with semiconductors. India's best semiconductor stocks have big tailwinds from defence and manufacturing.

10 Indian Companies with the Fastest Growth in Dividend Payouts...(Views On News)

Jan 10, 2022

These companies have been consistently paying higher dividends for several years.

Tata Steel vs SAIL: Which Stock is Better?(Views On News)

Jan 13, 2022

With government initiatives set to boost the steel sector, find out who has a better chance of coming out on top.

Watch Out for these 4 Indian Companies Betting Big on EV Supply Chain(Views On News)

Jan 11, 2022

The upside in supply chain players could be huge but a delay in the transition to EVs, or any policy related hiccups could end the momentum.

Tech Mahindra's CTC Acquisition: Too Expensive?(Views On News)

Jan 18, 2022

Tech Mahindra's acquisition of European IT-company fails to excite investors.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NORRIS MEDICINES SHARE PRICE


Jan 20, 2022 03:35 PM

TRACK NORRIS MEDICINES

  • Track your investment in NORRIS MEDICINES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON NORRIS MEDICINES

NORRIS MEDICINES 8-QTR ANALYSIS

COMPARE NORRIS MEDICINES WITH

MARKET STATS